![]() |
|
|
Vol. 31, Issue 4, 412-420, April 2003
Department of Basic Pharmaceutical Sciences, School of Pharmacy,
West Virginia University, Morgantown, West Virginia (J.L., S.S.E.,
D.B., G.D.S.) and Department of Pharmaceutical Sciences, Texas Tech
Health Sciences Center, School of Pharmacy, Amarillo, Texas (C.W.F.)
Key residue Val-382 in P450 1A1 has been predicted to interact with
the alkoxy chain of resorufin derivatives. Therefore, we
undertook a detailed analysis of substrate mobility in the active site
of the P450 1A1 homology model and assessed the effect of mutations at
position 382. Dynamic trajectories of 7-methoxy-, 7-ethoxy-, and
7-pentoxyresorufin indicated that 7-ethoxyresorufin would be oxidized
most efficiently by the wild-type enzyme. The Val-382
Ala mutation
would increase the O-dealkylation of 7-pentoxyresorufin but decrease the oxidation of other substrates. In the case of the
V382L mutant, the large bulk of Leu would block alkoxyresorufins from
productive binding orientations leading to lowered activities. Binding
free energy calculations for three substrates with 1A1 WT and two
mutants indicated that binding constants would be similar for all
enzyme-substrate combinations. Modeling predictions were tested
experimentally. The plasmid containing the cDNA for human P450 1A1
modified for bacterial expression was altered to include a C-terminal
PCR-generated six histidine domain to facilitate enzyme purification.
The V382A and V382L mutants were constructed by site-directed
mutagenesis and Escherichia coli-expressed enzymes purified using Ni-NTA affinity chromatography. The activity of the WT
1A1 was highest toward 7-ethoxyresorufin and lowest toward 7-pentoxyresorufin. Both mutants displayed a decrease in
Vmax with 7-methoxy- and 7-ethoxyresorufin,
whereas for the V382A mutant, Vmax with
7-pentoxyresorufin was increased. No significant changes in
Km were observed relative to the wild-type
enzyme. The experimental results are thus in good agreement with
modeling predictions.
This article has been cited by other articles:
![]() |
Y. Tu, R. Deshmukh, M. Sivaneri, and G. D. Szklarz Application of Molecular Modeling for Prediction of Substrate Specificity in Cytochrome P450 1A2 Mutants Drug Metab. Dispos., November 1, 2008; 36(11): 2371 - 2380. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Goldstone, H. M. H. Goldstone, A. M. Morrison, A. Tarrant, S. E. Kern, B. R. Woodin, and J. J. Stegeman Cytochrome P450 1 Genes in Early Deuterostomes (Tunicates and Sea Urchins) and Vertebrates (Chicken and Frog): Origin and Diversification of the CYP1 Gene Family Mol. Biol. Evol., December 1, 2007; 24(12): 2619 - 2631. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hirakawa, H. Iwata, Y. Takeshita, E.-Y. Kim, T. Sakamoto, Y. Okajima, M. Amano, N. Miyazaki, E. A. Petrov, and S. Tanabe Molecular Characterization of Cytochrome P450 1A1, 1A2, and 1B1, and Effects of Polychlorinated Dibenzo-p-dioxin, Dibenzofuran, and Biphenyl Congeners on Their Hepatic Expression in Baikal Seal (Pusa sibirica) Toxicol. Sci., June 1, 2007; 97(2): 318 - 335. [Abstract] [Full Text] [PDF] |
||||